- Home
- MESO vs NMRK Comparison
MESO vs NMRK Comparison
Compare MESO & NMRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MESO | NMRK |
|---|---|---|
| Founded | 2004 | 1929 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.1B |
| IPO Year | 2005 | 2017 |
Fundamental Metrics
Financial Performance| Metric | MESO | NMRK |
|---|---|---|
| Price | $11.96 | $11.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $37.00 | $18.33 |
| AVG Volume (30 Days) | 216.6K | ★ 1.7M |
| Earning Date | 08-26-2026 | 10-29-2026 |
| Dividend Yield | N/A | ★ 2.02% |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ 0.18 |
| Revenue | N/A | ★ $3,294,024,000.00 |
| Revenue This Year | $59.17 | $15.58 |
| Revenue Next Year | $59.00 | $8.49 |
| P/E Ratio | ★ N/A | $65.78 |
| Revenue Growth | N/A | ★ 20.29 |
| 52 Week Low | $12.94 | $11.38 |
| 52 Week High | $21.50 | $19.84 |
Technical Indicators
Market Signals| Indicator | MESO | NMRK |
|---|---|---|
| Relative Strength Index (RSI) | 28.02 | 28.57 |
| Support Level | N/A | N/A |
| Resistance Level | $15.97 | $16.13 |
| Average True Range (ATR) | 0.40 | 0.43 |
| MACD | -0.12 | -0.01 |
| Stochastic Oscillator | 2.03 | 2.01 |
Price Performance
Historical ComparisonAbout MESO Mesoblast Limited
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.
About NMRK Newmark Group Inc.
Newmark Group Inc is a commercial real estate advisory firm. It offers services, including leasing and corporate advisory services, investment sales, commercial mortgage brokerage, appraisal and valuation, project management, and property, among others. Newmark offers a diverse array of integrated services and products designed to meet the full needs of both real estate investors/owners and occupiers. The company provides real estate strategic consulting and systems integration services to CFI's clients including many Fortune and Forbes companies, owner-occupiers, government agencies, healthcare, and higher education clients.